Loncastuximab Tesirine: First Approval.

Abstract

Loncastuximab tesirine (loncastuximab tesirine-lpyl; ZYNLONTA™) is an antibody-drug conjugate being developed for the treatment of B cell lymphomas by ADC Therapeutics SA. Loncastuximab tesirine consists of a pyrrolobenzodiazepine DNA-alkylating warhead covalently attached via a cleavable linker to an anti-CD19 antibody that binds to B cells. It is currently approved in the US for the treatment of relapsed/refractory diffuse large B cell lymphoma (DLBCL), and is being developed for the treatment of mantle-cell lymphoma, follicular lymphoma and acute lymphoblastic leukaemia. This article summarizes the milestones in the development of loncastuximab tesirine leading to this first approval for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified (NOS), DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.

• Authors: Arnold Lee
• Journal: Drugs (Drugs) Vol. 81 Issue 10 Pg. 1229-1233 (Jul 2021) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 34143407 (Publication Type: Journal Article, Review)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents, Immunological
• Benzodiazepines
• loncastuximab tesirine

Topics

• Antibodies, Monoclonal, Humanized (adverse effects, pharmacology, therapeutic use)
• Antineoplastic Agents, Immunological (adverse effects, pharmacology, therapeutic use)
• Benzodiazepines (adverse effects, pharmacology, therapeutic use)
• Clinical Trials as Topic
• Drug Approval
• Humans
• Lymphoma, B-Cell (drug therapy)
• United States
• United States Food and Drug Administration